Effect of Erythropoietin on Neurodevelopmental Outcomes in Very Preterm Infants With Intraventricular Hemorrhage

• Status: Completed
• Trial end date: 2019-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Erythropoietin (EPO) has been shown to be neurotrophic and neuroprotective in several animal models and some clinical studies. Our hypothesis is that EPO could improve long-term neurological outcomes in very preterm infants with intraventricular hemorrhage (IVH). The aim of this study is to evaluate the long-term neuroprotective effect of repeated low-dose EPO (500 U/kg) in very preterm infants with IVH.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhengzhou University
• Collaborators: Göteborg University; Zhengzhou Children's Hospital, China
• Treatments: Epoetin Alfa

Criteria

Inclusion Criteria:

• Preterm infants admitted to NICU ≤ 32 weeks gestation at birth

• Birth weight less than 1500 g

• Less than 72 hours of life at time of enrolment

• Diagnosed as IVH by head ultrasound

• Written informed consent of parent or guardian

Exclusion Criteria:

• Genetic metabolic diseases

• Congenital abnormalities

• Polycythaemia (Hct > 65%) within first 24 hours of life

• Thrombocytopenia (platelets < 50K cells/microL) within first 24 hours of life

• Unstable vital signs (such as respiration and circulation failure)